MARKET

HURA

HURA

TuHURA Biosciences
NASDAQ
1.980
+0.070
+3.66%
Closed 19:33 12/04 EST
OPEN
1.910
PREV CLOSE
1.910
HIGH
2.000
LOW
1.900
VOLUME
86.24K
TURNOVER
907.27K
52 WEEK HIGH
7.20
52 WEEK LOW
1.560
MARKET CAP
101.49M
P/E (TTM)
-1.2340
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HURA last week (1124-1128)?
Weekly Report · 4d ago
TuHURA Biosciences’ Shelf Registration Statement Effective
TipRanks · 11/25 13:28
Tuhura Biosciences Completes Private Placement of Common Stock and Warrants
Reuters · 11/25 13:02
Weekly Report: what happened at HURA last week (1117-1121)?
Weekly Report · 11/24 10:36
TuHURA Biosciences Completes Acquisition of Kineta, Inc.
TipRanks · 11/18 22:30
TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded?
Seeking Alpha · 11/17 12:53
Weekly Report: what happened at HURA last week (1110-1114)?
Weekly Report · 11/17 10:37
TuHURA Biosciences Reports Q3 Financials and Advances Cancer Therapy Trials
TipRanks · 11/15 01:02
More
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Webull offers TuHURA Biosciences Inc stock information, including NASDAQ: HURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HURA stock methods without spending real money on the virtual paper trading platform.